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A B S T R A C T
Objectives: The aim of this study was to elucidate patterns of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) clearance in the natural course of asymptomatic coronavirus disease 2019
(COVID-19).
Methods: Consecutive patients with non-severe COVID-19 were included retrospectively. Asymptomatic
patients with a normal body temperature and no evidence of pneumonia throughout the disease course
were assigned to the asymptomatic group. The reverse transcription PCR (RT-PCR) assay was repeated
every two to five days after the first follow-up RT-PCR assay. Negative conversion was defined as two
consecutive negative RT-PCR assay results within a 24-h interval. Rebound of the cycle threshold (Ct)
value was defined as negative from the single RT-PCR assay and positive from the following assay.
Results: Among a total of 396 patients identified (median age 42.5 years (interquartile range (IQR) 25.0–
55.0 years), 35.6% male), 68 (17.2%) were assigned to the asymptomatic group and 328 (82.8%) to the
symptomatic group. The time until negative conversion was significantly shorter in the asymptomatic
group than in the symptomatic group: median 14.5 days (IQR 11.0–21.0 days) and 18.0 days (IQR 15.0–
22.0 days), respectively (p = 0.001). Rebound of Ct values was observed in 78 patients (19.7%).
Conclusions: Time until negative conversion is shorter in asymptomatic COVID-19 than in symptomatic
COVID-19. Rebound of Ct values is not uncommon.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The first cases of coronavirus disease 2019 (COVID-19) were
reported in Wuhan, China in December 2019 (Chen et al., 2020;
Huang et al., 2020). The pathogen has been identified as severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lu et al.,
2020; Zhu et al., 2020). COVID-19 has rapidly become widespread
across the world. In March 2020, the World Health Organization
declared the COVID-19 outbreak a pandemic. From the end of
February through March 2020, Daegu—the fourth largest city in
South Korea—was emerging as an epicenter of COVID-19 in South
Korea. The government of South Korea recommended that allciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
280 J.-S. Uhm et al. / International Journal of Infectious Diseases 99 (2020) 279–285people who had been in contact with a patient with COVID-19 or
had visited locations where outbreaks had occurred should be
tested, even if they did not have symptoms. In the early phase of
the outbreak, individuals who were diagnosed with COVID-19
were required to be hospitalized for quarantine, regardless of
disease severity. As the number of patients increased, the hospitals
started to run out of rooms. For this reason, asymptomatic and
mildly symptomatic patients were quarantined in dedicated
COVID-19 facilities and moderately to severely symptomatic
patients were hospitalized in dedicated COVID-19 hospitals (Park
et al., 2020; Choi et al., 2020).
The clinical features of COVID-19 range from asymptomatic to
critical illness. Epidemiological surveys have shown evidence that
SARS-CoV-2 can be contagious in the presymptomatic stages of
COVID-19 (Rothe et al., 2020; Ye et al., 2020). Furthermore, it is
known that persistently asymptomatic COVID-19 is transmissible
(Bai et al., 2020). Cases of asymptomatic COVID-19 represent an
emerging and serious public health issue given their elusive and
contagious characteristics. However, patterns of SARS-CoV-2
clearance in asymptomatic COVID-19 remain unclear.
The aim of this study was to elucidate changes in results of real-
time reverse transcription polymerase chain reaction (RT-PCR) for
SARS-CoV-2 and the time until negative conversion in the natural
course of asymptomatic COVID-19 compared with symptomatic
non-severe COVID-19.
Methods
This was a retrospective cohort study. Consecutive patients of
all ages who were hospitalized in one of two dedicated COVID-19
hospitals (Korea Workers’ Compensation and Welfare Services
Daegu Hospital and Chungju Medical Center) after the diagnosis of
non-severe COVID-19 by real-time RT-PCR for SARS-CoV-2,
performed on specimens from a nasopharyngeal swab between
February 24 and April 2, 2020, were included retrospectively.
The severity of COVID-19 was defined using the current
guidelines for the diagnosis and treatment of community-acquired
pneumonia (Metlay et al., 2019). Patients with severe COVID-19
and patients in whom negative conversion was not confirmed were
excluded. Patients with no COVID-19-related symptoms, a body
temperature 37.4 C, and no evidence of pneumonia based on
chest X-rays throughout the disease course were assigned to the
asymptomatic group. Patients with COVID-19-related symptoms, a
body temperature 37.5 C, or findings compatible with pneumo-
nia based on chest X-rays or computed tomography (CT) were
assigned to the symptomatic group. COVID-19-related symptoms
included newly developed cough, sputum, sore throat, rhinorrhea,
headache, chest pain, fever, chills, myalgia, dyspnea, anosmia,
ageusia, and diarrhea.
Laboratory tests including complete blood cell count and blood
chemistry were performed upon admission. Supportive care was
given for the asymptomatic patients, while treatment for specific
symptoms with or without antimicrobial therapy was provided for
the symptomatic patients. Antimicrobial therapy included lopi-
navir/ritonavir, hydroxychloroquine, third-generation cephalospo-
rin, and azithromycin.
During hospitalization, the first follow-up RT-PCR assay for
SARS-CoV-2 was performed on specimens from a nasopharyngeal
swab, 7 days after diagnosis for the asymptomatic patients and
immediately after the disappearance of symptoms or improve-
ment in pneumonia stage for the symptomatic patients. When the
follow-up RT-PCR assay was negative, the following RT-PCR assay
was performed on specimens from a nasopharyngeal swab after
24–48 h. When the follow-up RT-PCR assay was positive, the
following RT-PCR assay was performed on specimens from a
nasopharyngeal swab after two to five days.For the patients hospitalized in the Korea Workers’ Compensa-
tion and Welfare Services Daegu Hospital, RT-PCR assays for the E
(envelop protein) and RdRP (RNA-dependent RNA polymerase)
genes were performed with the PowerChek 2019-nCoV Assay
(Kogene Biotech Inc., Seoul, South Korea) in a Bio-Rad CFX96 Deep
Well real-time PCR detection system (Bio-Rad, Hercules, CA, USA),
after viral RNA extraction using an NX-48 viral nucleic acid
extraction kit (Genolution, Seoul, South Korea) in conjunction with
Nextractor NX-48 (Genolution) at Samkwang Medical Laborato-
ries. A positive test result was defined as a well-defined
exponential fluorescence curve that crossed the threshold (cycle
threshold (Ct) value) at 35 cycles for the E genes or the RdRP
genes, respectively.
For the patients hospitalized in Chungju Medical Center, the RT-
PCR assays for the E gene, RdRP gene, and N gene (nucleocapsid
protein) were performed with the Allplex 2019-nCoV Assay
(Seegene Inc., Seoul, South Korea) in a Bio-Rad CFX96 Deep Well
real-time PCR detection system (Bio-Rad, Hercules, CA, USA), after
viral RNA extraction using a MagNA Pure 96 DNA and Viral NA
Small Volume Kit (Roche Molecular Biochemicals, Indianapolis, IN,
USA) in conjunction with the MagNa Pure 96 System (Roche
Molecular Biochemicals) at Seegene Medical Foundation. The
cutoff values for the RT-PCR assays were defined as Ct values of
33.5, 33.5, and 34.5 for the E, RdRP, and N gene, respectively (Hong
et al., 2020).
Negative conversion was defined as two consecutive negative
RT-PCR assay results within a 24-h interval. Patients with negative
conversion were released from quarantine and discharged. The
time until negative conversion was defined as the interval between
diagnosis and the first RT-PCR-negative result at negative
conversion. Rebound of the Ct value was defined as negative from
the single RT-PCR assay and positive from the following RT-PCR
assay.
The following were compared between the asymptomatic and
symptomatic groups: baseline characteristics, laboratory findings
at admission, positive RT-PCR rate each week (defined as the
number of patients with a positive result divided by the number of
patients who underwent RT-PCR assay testing), time until negative
conversion, and the first follow-up Ct values and minimum follow-
up Ct values for the E, RdRP, and N genes, as well as the changes in
Ct values.
Statistical analysis
Continuous data are expressed as the median value with
interquartile range (IQR), while categorical data are presented as
the number and percentage (%). The Mann–Whitney U-test for
continuous data and Fisher’s exact test for categorical data were
used to compare the clinical parameters between the two groups,
as all datasets were non-normally distributed. A p-value < 0.05 for
a two-sided test was considered statistically significant. Data were
analyzed using IBM SPSS Statistics version 25.0 (IBM Corp.,
Armonk, NY, USA).
Results
A total of 422 patients were screened (median age 45.0 years
(IQR 26.0–55.0 years), 36.0% male). Among them, 70 patients
(16.6%) were asymptomatic throughout the disease course.
Twenty-two patients were excluded because they were referred
to the high-level hospitals due to worsening of their condition.
Four patients were excluded because their negative conversion
was not confirmed. Therefore, a total of 396 consecutive patients
were included in this study. Their median age was 42.5 years (IQR
25.0–55.0 years, range 5–82 years) and 35.6% were male; 289
patients were from the Korea Workers’ Compensation and Welfare
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Medical Center. Among the 396 patients, 68 (17.2%) were assigned
to the asymptomatic group and 328 (82.8%) to the symptomatic
group. The baseline characteristics are shown in Table 1.
Pulse rate, body temperature, white blood cell count, and C-
reactive protein levels were significantly higher in the symptom-
atic group than in the asymptomatic group. All patients withTable 1
Baseline characteristics; continuous data are expressed as median values (interquartile
Asymptomatic g
Age (years) 33.5 (23.8–56.3
Sex 
Male 31 (45.6) 
Female 37 (54.4) 
Body mass index (kg/m2) 22.4 (20.5–24.8
Overweight 15 (22.1) 
Obese 0 (0) 
Symptoms
Cough 0 (0) 
Sputum 0 (0) 
Sore throat 0 (0) 
Rhinorrhea 0 (0) 
Headache 0 (0) 
Chest pain 0 (0) 
Fever/chills 0 (0) 
Myalgia 0 (0) 
Dyspnea 0 (0) 
Anosmia 0 (0) 
Ageusia 0 (0) 
Diarrhea 0 (0) 
Interval between symptom onset and diagnosis (days) – 
Past history 14 (20.6) 
Asthma 0 (0) 
COPD 0 (0) 
Hypertension 11 (16.2) 
Diabetes 3 (4.4) 
Coronary artery disease 0 (0) 
Dyslipidemia 1 (1.5) 
Prior medications
ACEI/ARB 6 (8.8) 
Calcium channel blocker 2 (2.9) 
Statin 2 (2.9) 
Biguanide 2 (2.9) 
Systolic BP (mmHg) 129.0 (118.5–13
Diastolic BP (mmHg) 78.0 (72.0–83.5
Pulse rate (/min) 80.0 (71.0–90.3
Respiration rate (/min) 20.0 (19.0–20.0
Body temperature (C) 36.9 (36.9–37.1)
Body temperature 37.5 C 0 (0) 
O2 saturation (%) 97.0 (97.0–98.0)
Chest X-ray or CT findings
Unilateral pneumonia 0 (0) 
Bilateral pneumonia 0 (0) 
Laboratory findings
Hemoglobin (g/dl) 13.8 (13.4–15.2)
WBC count (/ml) 5195 (4458–583
Neutrophil (%) 53.7 (48.3–60.9
Lymphocyte (%) 34.2 (29.4–39.8
Platelet count (/ml) 261 000 (243 0
BUN (mg/dl) 12.0 (10.8–13.7)
Creatinine (mg/dl) 0.9 (0.7–1.0) 
AST (U/L) 20.0 (16.8–23.0
ALT (U/L) 19.5 (12.8–27.0)
LDH (IU/L) 214.0 (180.0–23
CRP (mg/dl) 0.1 (0.1–0.1) 
Antimicrobial therapy
Lopinavir/ritonavir 0 (0) 
Hydroxychloroquine 0 (0) 
Third-generation cephalosporin 0 (0) 
Azithromycin 0 (0) 
ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, an
BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRP, C-reactive
cell.
a Statistical comparison could not be performed because the number of patients waobesity, asthma, chronic obstructive pulmonary disease, and
coronary artery disease had COVID-19-related symptoms and
were therefore included in the symptomatic group. There was no
significant difference in age, sex, body mass index, past histories,
prior medications, blood pressure, respiration rate, hemoglobin,
proportions of neutrophils and lymphocytes, platelet count, blood
urea nitrogen, creatinine, aspartate aminotransferase, alanine range) and categorical data are presented as numbers (%).
roup (n = 68) Symptomatic group (n = 328) p-Value































5.0) 129.0 (119.0–139.0) 0.462
) 78.0 (70.0–85.0) 0.655
) 85.0 (77.0–94.0) 0.008
) 20.0 (20.0–20.0) 0.816
 37.0 (36.7–37.4) 0.004
71 (21.6) -a
 97.0 (97.0–98.0) 0.989
53 (16.2) -a
61 (18.6) -a
 13.7 (12.8–14.9) 0.307
5) 5825 (4855–6905) 0.007
) 57.2 (49.6–63.5) 0.091
) 31.9 (26.5–38.8) 0.106
00–309 000) 258 000 (220 000–306 000) 0.353
 11.9 (10.0–14.3) 0.889
0.8 (0.7–0.9) 0.012
) 21.0 (17.0–28.0) 0.199
 20.0 (13.0–31.8) 0.788






giotensin II receptor blocker; AST; aspartate aminotransferase; BP, blood pressure;
 protein; CT, computed tomography; LDH, lactate dehydrogenase; WBC, white blood
s small.
Table 2
Data on follow-up RT-PCR assays for SARS-CoV-2; Continuous data are expressed as median values (interquartile range) and categorical data are presented as numbers (%).
Asymptomatic group (n = 68) Symptomatic group (n = 328) p-Value
Interval between diagnosis and the first follow-up RT-PCR assay (days) 9.5 (7.0–14.0) 16.0 (13.0–19.0) <0.001
Number of follow-up RT-PCR assays 3.0 (2.0–5.0) 2.0 (2.0–4.0) 0.055
Median interval between follow-up RT-PCR assays (days) 2.0 (1.0–4.0) 2.0 (1.0–3.0) 0.430
Time until negative conversion (days) 14.5 (11.0–21.0) 18.0 (15.0–22.0) 0.001
Rebound of Ct value 15 (22.1) 63 (19.2) 0.616
Ct, cycle threshold; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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groups. All patients in both groups were discharged from the
hospital without any sequelae.
Data on the follow-up RT-PCR assays for SARS-CoV-2 are shown
in Table 2. The interval between diagnosis and the first follow-up
RT-PCR assay was significantly shorter in the asymptomatic group
than in the symptomatic group. There was no significant difference
in the number of follow-up RT-PCR assays or median interval
between follow-up RT-PCR assays between the two groups. The
time until negative conversion was significantly shorter in the
asymptomatic group than in the symptomatic group: median 14.5
days (IQR 11.0–21.0 days, range 6.0–40.0 days) and median 18.0
days (IQR 15.0–22.0 days, range 4.0–46.0 days), respectively
(p = 0.001).
The proportion of patients with negative conversion according
to the time until negative conversion in the asymptomatic and
symptomatic groups is shown in Figure 1. In the asymptomatic
group, negative conversion was achieved within 1 week in 11.8%, 2
weeks in 50.0%, 3 weeks in 76.5%, 4 weeks in 92.6%, and 5 weeks in
98.5% of the patients. In the asymptomatic group, negative
conversion was not achieved within 30 days in 5.9% of the
patients. In contrast, in the symptomatic group, negative conver-
sion was achieved within 1 week in 2.7%, 2 weeks in 21.6%, 3 weeks
in 74.1%, 4 weeks in 89.9%, and 5 weeks in 97.9% of the patients. In
the symptomatic group, negative conversion was not achieved
within 30 days in 6.7% of the patients.
Changes in the proportion of patients without negative conver-
sion according to hospitalization day are shown in Figure 2. The
proportion of patients with negative conversion within 20 days was
significantly higher in the asymptomatic group than in the
symptomatic group, while the proportion of patients with negative
conversion in 20 days was similar in the two groups. There was no
significant difference in the positive RT-PCR rate between the groups
on days 7, 14, 21, and 28 since diagnosis among the patients who
underwent follow-up RT-PCR assays (Table 3).Figure 1. The proportion of patients with negative conversion according to time unRT-PCR assays for the E and RdRP genes were performed for all
patients, while the RT-PCR assay for the N gene was performed for
107 patients. There was no significant difference in the first follow-
up Ct value for the E, RdRP, and N genes between the two groups
(Supplementary Material Table S1). There was no significant
difference in minimum follow-up Ct value of the E, RdRP, and N
genes between the two groups (Supplementary Material Table S1).
There was no significant difference in rebound of Ct values
between the two groups (Table 2). Serial changes in Ct values for
the three genes in the asymptomatic and symptomatic groups are
shown in Figure 3.
Discussion
Main findings of this study
The main findings of this retrospective cohort study were as
follows: (1) approximately 17% of the patients with COVID-19
exhibited no symptoms; (2) all of the patients with obesity,
asthma, chronic obstructive pulmonary disease, and coronary
artery disease had COVID-19-related symptoms; (3) the median
time from diagnosis to negative conversion was approximately 2
weeks in the natural course of asymptomatic COVID-19–that is,
negative conversion was not achieved 2 weeks after diagnosis in
approximately half of the asymptomatic patients with COVID-19;
(4) time until negative conversion was shorter in asymptomatic
COVID-19 than in symptomatic COVID-19; (5) rebound of Ct values
was not uncommon in follow-up RT-PCR assays; and (6) there was
no significant difference in rebound of Ct values between the
asymptomatic and symptomatic patients.
Prior studies on asymptomatic COVID-19
Given that asymptomatic cases are known to play a role in
disease transmission (Bai et al., 2020; Pan et al., 2020a, b; Rothetil negative conversion in the asymptomatic (A) and symptomatic (B) groups.
Figure 2. Changes in the proportion of patients without negative conversion
relative to hospitalization day.
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such cases relative to symptomatic cases and the characteristics of
viral shedding in asymptomatic infection to establish guidelines
for the management of COVID-19. The proportion of asymptomatic
infection has been estimated to be 17.9–30.8% (Mizumoto et al.,
2020; Nishiura et al., 2020).
If patients have no symptoms at the time of diagnosis, it is
difficult to distinguish persistently asymptomatic patients
throughout the disease course from patients in the presymptom-
atic period. According to a report on 13 asymptomatic patients
with COVID-19, 12 patients had radiological abnormalities and
three patients developed symptoms (Zhou et al., 2020). Approxi-
mately 9.6% of residents in Wuhan, China who had never been
symptomatic yet were diagnosed with COVID-19 exhibited
positive IgG-antibody test results for SARS-CoV-2, suggesting that
they had had an asymptomatic infection (Wu et al., 2020). The
results of the present study are consistent with prior findings that
the Ct values in asymptomatic patients are not significantly
different from those in symptomatic patients (Zou et al., 2020).
A previous study demonstrated that the time from diagnosis to
negative conversion was 7.5 days in persistently asymptomatic
patients with normal or atypical chest CT findings and 12.5 days in
persistently asymptomatic patients with pneumonia (Pan et al.,
2020a, b). There was a difference in the time until negative
conversion between this previous study and the present study. This
might be because the interval from disease onset to diagnosis was
longer in the previous study than in the present study. Another
previous study showed that asymptomatic patients had a longer
duration of viral shedding than symptomatic patients, in contrast
to the present study (Long et al., 2020). It has been suggested that
asymptomatic cases show relatively smaller transmission rates
than symptomatic cases (He et al., 2020).Table 3
Positive RT-PCR rates at each week among the patients who underwent follow-up RT-PCR
results)/(the number of patients who underwent RT-PCR assay) and the percentage (%
Positive RT-PCR rate on the following days since diagnosis: Asymptom
Day 7 14/22 (63.6
Day 14 19/53 (35.8
Day 21 13/65 (20.0
Day 28 4/67 (6.0) 
RT-PCR, reverse transcriptase polymerase chain reaction.Differences in baseline characteristics between the groups
In Daegu, South Korea, mass investigation and mass testing, as
well as active surveillance, have been performed throughout the
COVID-19 outbreak. As a result, a number of asymptomatic
patients with COVID-19 were detected. Among the population in
this study, 95.5% of the patients were residents of Daegu. While
hospital beds were limited, some asymptomatic or mildly
symptomatic patients with COVID-19 were quarantined at home
or in dedicated COVID-19 facilities. Therefore, the proportion of
asymptomatic patients in this study might be underestimated.
In the present study, all COVID-19 patients with obesity,
asthma, chronic obstructive pulmonary disease, and coronary
artery disease had symptoms. This might be because they are
susceptible to the development of COVID-19-related symptoms or
because symptoms related to these underlying diseases might be
confused with COVID-19-related symptoms. In the symptomatic
patients, body temperature, white blood cell count, and the C-
reactive protein level were higher than in the asymptomatic
patients. These findings suggest that symptomatic patients might
mount a stronger inflammatory reaction than asymptomatic
patients. A high pulse rate may be associated with a high body
temperature in symptomatic patients.
Clinical implications of this study
Although it was unclear when exposure to SARS-CoV-2 may
have occurred, the median duration of disease in asymptomatic
COVID-19 must be longer than 14.5 days. The reasons for the
shorter time until negative conversion in the asymptomatic
patients might have been because of a short disease duration or
delayed diagnosis. The optimal time at which the first follow-up
RT-PCR assays should be performed in asymptomatic patients can
be decided based on the present study results. Rebound of Ct
values was observed in a considerable number of patients.
Although the reasons for rebound of Ct values remain unclear,
possible explanations include reactivation of SARS-CoV-2, inade-
quate specimen collection, and laboratory errors. In any case,
negative results for two consecutive RT-PCR assays within a 24-h
interval can be considered a reasonable criterion for lifting the
quarantine.
No studies have yet dealt with the clinical characteristics and
viral kinetics of a larger number of asymptomatic patients, and
studies reporting comparisons of the characteristics and changes
in RT-PCR results in asymptomatic patients with those in
symptomatic patients are also scarce. The results of the present
study provide the rationale for a quarantine strategy for
asymptomatic people who have been exposed to patients with
COVID-19, including recommendations on when best to perform
follow-up RT-PCR assays for asymptomatic patients with COVID-19
in the midst of shortages of medical facilities and equipment
during the COVID-19 outbreak. assays; positive RT-PCR rates are expressed as (the number of patients with positive
).
atic group (n = 68) Symptomatic group (n = 328) p-value
) 15/24 (62.5) 0.936
) 54/125 (43.2) 0.362
) 57/300 (19.0) 0.853
27/322 (8.4) 0.507
Figure 3. Changes in Ct value from RT-PCR assays for the E gene of SARS-CoV-2 in the asymptomatic (A) and symptomatic (B) groups, RdRP gene of SARS-CoV-2 in the
asymptomatic (C) and symptomatic (D) groups, and N genea of SARS-CoV-2 in the asymptomatic (E) and symptomatic (F) groups. Each line represents one patient.
aThe RT-PCR assay for the N gene was performed in 23 patients in the asymptomatic group and 84 patients in the symptomatic group.
Ct, cycle threshold; E, envelop protein; N, nucleocapsid protein; RdRP, RNA-dependent RNA polymerase; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-
2, severe acute respiratory syndrome coronavirus 2.
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This study had several limitations. First, the time of exposure to
SARS-CoV-2 was unclear for a number of patients. Therefore, it was
difficult to specify the onset of the disease in asymptomatic
patients. Second, only nasopharyngeal specimens were collectedfrom all patients. RT-PCR positivity can be higher or more
prolonged for lower respiratory specimens (Sethuraman et al.,
2020; Wang et al., 2020). Third, the Ct values at diagnosis were
unavailable. Fourth, given that the present study was retrospective,
the follow-up intervals of RT-PCR assays lacked uniformity and
density. In particular, the intervals between diagnosis and the first
J.-S. Uhm et al. / International Journal of Infectious Diseases 99 (2020) 279–285 285follow-up RT-PCR assay differed between the asymptomatic and
symptomatic groups because existing recommendations on when
to perform the first follow-up RT-PCR assay were different in the
two groups. Fifth, the RT-PCR assay for the N gene was not
performed in all patients. Sixth, Ct values may not be linearly
correlated to viral load. Seventh, chest CT was not performed in all
patients. Specifically, the patients with normal chest X-ray results
did not undergo chest CT.
Despite these limitations, this study had several strengths. A
significant number of asymptomatic patients were included. Serial
RT-PCR results were analyzed throughout the disease course.
These findings may contribute to establishing guidelines for the
management of asymptomatic COVID-19 in pandemic situations
and shortages of medical resources.
Conclusions
Time until negative conversion is shorter in asymptomatic
COVID-19 than in symptomatic COVID-19. Rebound of Ct values is
not uncommon.
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